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Background. Toxic shock syndrome is a potentially fatal toxin-mediated disease. The role of toxins in this clinical entity made
us hypothesize that extracorporeal blood purification with CytoSorb could play a beneficial role in the clinical management of
toxic shock syndrome. This case report describes the successful treatment of toxic shock syndrome using a combination of renal
replacement therapy andhemadsorption in a pediatric patient.Case Presentation. A 5-year-old girl withDown’s syndromepresented
with an inflamed area surrounding an insect bite, signs of systemic inflammation, andmultiple organ failure. As previous attempts of
immune modulation therapy were unsuccessful, renal replacement therapy was supplemented by the cytokine absorber CytoSorb.
Treatment using this combination was associated with a rapid and significant stabilization in the hemodynamic situation and a
decrease in inflammatory mediators within hours after the initiation of therapy. The application of CytoSorb therapy was simple
and safe. Conclusion. The use of extracorporeal blood purification with CytoSorb proved potentially beneficial by removing toxins
and inflammatory mediators in this case and could therefore play a role in the clinical management of toxic shock syndrome.
Whether CytoSorb has the potential to even positively influence mortality in patients with toxic shock syndrome still needs to be
confirmed.
1. Introduction
Toxic shock syndrome (TSS) is a potentially fatal toxin-
mediated disease caused by infection from Staphylococcus
aureus or Group A Streptococcus (GAS). This multisystem
disorder is the consequence of an uncontrolled systemic
inflammatory response syndrome caused by bacterial super-
antigens that broadly activate T-cells and lead to hyper-
cytokinemia and hyperinflammation [1]. Consequently, the
excessive release of various cytokines, leukotrienes, and
prostaglandins, causing a “cytokine storm,” leads to the gen-
eration of the symptoms of this syndrome.The goal of therapy
in TSS is to eradicate infection, mitigate the overwhelm-
ing inflammatory response, and prevent complications.
Therefore, the fatal role of toxins in this disease entity made
us hypothesize that extracorporeal blood purification with
a novel sorbent, CytoSorb, might be capable of removing
toxins, cytokines, and other inflammatory mediators and
could play a beneficial role in the clinicalmanagement of TSS.
This case report describes the successful treatment of toxic
shock syndrome using CytoSorb in a five-year-old girl with
Down’s syndrome. Consent on publishing has been gathered
from the patients’ legal parents.
2. Case Report
A 5-year-old girl with Down’s syndrome presented with an
erythematous, indurated area on her right leg surrounding an
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insect bite noticed two days prior to admission. Oral cefaclor
therapy was started for suspected systemic infection by
S. pyogenes or S. aureus/epidermidis the day before admission
by the GP. Despite antibiotics, the erythema continued to
migrate proximally towards the inguinal region. On arrival
at the emergency department, the conscious patient pre-
sented with diarrhea but stable vital signs: breathing rate
26 breaths/min, heart rate 110 beats/min, and blood pres-
sure 98/57mmHg. Blood examination revealed leukocytosis
(15.44G/L), neutrophilia (84.8%, absolute or 13.1 G/L), mild
anemia (Hb 107 g/L, Hct 32%), a normal platelet count
(238G/L), and an elevated CRP (260.98mg/L).
During the first two hours her status deteriorated so
rapidly that she needed to be transferred to the intensive care
unit. Capillary blood gas analysis revealed a severe uncom-
pensated metabolic acidosis: pH 6.77, pCO2 37.6mmHg,
HCO3 5.2mmol/L, and lactate 7mmol/L. Septic shock was
diagnosed and three intravenous fluid boluses (20mL/kg)
and oxygen therapy were started. Blood cultures were taken
and the antibiotic therapy augmented by parenteral clin-
damycin and vancomycin. Due to an unsatisfactory car-
diovascular response to fluid resuscitation, dopamine was
started at 5𝜇g/kg/min and then increased to 10 𝜇g/kg/min.
Low ventricular contractility on ultrasonography required
additional dobutamine at 5 𝜇g/kg/min while clinical signs
of decreased systemic vascular resistance necessitated nora-
drenaline at 0.1𝜇g/kg/min which had to be increased up
to 0.5 𝜇g/kg/min later. Due to pronounced cardiovascular
instability and suspected adrenal gland insufficiency, hydro-
cortisone was prescribed at 2mg/kg/12 hours.
Considering the well-known immunodeficiency of
patients with Down’s syndrome, an antimycotic agent
(fluconazole) was administered preventively, and intravenous
immunoglobulin therapy (1 g/kg) for septic shock due to
S. pyogenes or S. aureus was given on the day of admission
and the following day. Fresh frozen plasma (15mL/kg)
and low molecular weight heparin (enoxaparin 6mg/kg)
were administered for laboratory signs of disseminated
intravascular coagulation (DIC). Deep vein thrombosis
of the right lower extremity was ruled out by Doppler
ultrasonography. Chest X-ray revealed increased perihilar
lung markings.
Eight hours after admission to the ICU an altered state
of consciousness, hypercapnia, tachydyspnoe, and increasing
oxygen needs required intubation and pressure controlled
SIMV at PIP 17 cm H2O, PEEP 5 cm H2O, respiratory rate
25/min, and FiO2 0.4.
Based on the Surviving Sepsis Campaign guidelines
multiorgan failure was diagnosed. The patient had cardio-
vascular instability requiring complex vasoactive therapy
(dopamine, dobutamine, noradrenaline, andmilrinone);DIC
indicated deteriorating liver function, poor lung function
on ventilatory support alluding to Acute Respiratory Dis-
tress Syndrome (ARDS), and deteriorating kidney function.
Microbiological examinations were inconclusive as to the
causative pathogen.
During the first 48 hours of therapy diffuse erythro-
derma with purpura and petechiae appeared, while the right
leg became livid, and bullae appeared in places subjected
Figure 1: Diffuse erythroderma, purpura, and petechiae with severe
generalized edema (A). Erythroderma, livid swelling, confluent
bullae, and diffuse desquamation of the right leg (B, C). Arrow
indicates site of the initial insect bite.
to external pressure (Figure 1). Periodic pediatric surgery
consultation excluded necrotizing fasciitis. The clinical pic-
ture now matched that of TSS. While skin lesions improved
gradually and necrotic areas recovered fully under local
conservative therapy from day seven onwards, new bullous
eruptions continued to appear.
In an attempt to modulate the dysregulated immune
response, plasma exchange therapy was performed without
complications. Despite an increasing urine output during
the first 24 hours from 0.4 to 5.4ml/kg/hour her fluid
balance remained positive. Thereafter, diuresis declined and
the patient became anuric by hour 56 such that continuous
venovenous hemodialysis was started. Thrombocytopenia,
anemia, and hypoproteinemia were supported by blood
products and an augmentation of the low neutrophil levels
by granulocyte-colony stimulating factor tried on days four
and five.
As previous attempts of immune modulation therapy
were unsuccessful, renal replacement therapy was supple-
mented by the cytokine absorber CytoSorb (Cytosorbents
Corp., Monmouth Junction, NJ, USA). CVVHD was per-
formed withmultiFiltrate (FreseniusMedical Care) machine,
using a AV400S polysulfone dialyzer. Blood flow (𝑄b) of
40mL/min could be achieved; dialysis fluid (MultiBic) flow
(𝑄d) of 800mL/hour was maintained, with an ultrafiltration
rate of 100mL/hour. Because of hepatic failure with DIC,
regional citrate anticoagulation was used during the whole
course of CRRT without any remarkable complication. As
a result of a 72-hour uneventful course of the CVVHD-
CytoSorb therapy, cardiovascular stability improved on lower
vasopressor doses; FiO2 decreased from 0.95 to 0.4, air-
way pressures PIP/PEEP from 27/10 to 24/8 cm H2O, and
respiratory rate from 25 to 15/min, respectively. In addi-
tion, levels of important laboratory parameters decreased
(Table 1) as did plasma concentrations of proinflamma-
tory and immunomodulatory cytokines (Figure 2). This
attenuation of the inflammatory response correlated with
the clinical improvement. The need for platelets decreased
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Table 1: Laboratory parameters during the course of multiple immune-modulatory therapies including CVVHD + CytoSorb.
Time from
admission pH
Lactate
[mmol/L]
CRP
[mg/L]
PCT
[𝜇g/L]
WBC
[103/𝜇L]
Platelets
[103/𝜇L]
BUN
[mmol/L]
Creatinine
[𝜇mol/L]
ALT
[U/L]
AST
[U/L]
LDH
[U/L]
0 6,42 8.6 178.7 218.4 14.97 204 10.5 196 38 21 344
6 hr Start of hydrocortisone, IVIG
15 hr 7.35 4.4 114 95.07 8.67 67 11.1 134 — — —
42 hr 7.37 3.9 105.1 32.85 7.72 34 17.3 147 — — —
63 hr 7.39 3.6 113.5 20.54 8.15 12 24.3 210 — — —
67 hr Start of plasma exchange therapy
69 hr 7.39 4.2 87.46 19.02 6.96 21 26.4 223 270 150 887
78 hr Start of CVVHD-CytoSorb
91 hr 7.41 1.9 50.5 4.06 1.91 5 18.8 163 214 101 554
133 hr 7.47 1.5 87.46 3.33 4.31 5 12.8 98 274 146 676
150 hr End of CVVHD-CytoSorb
212 hr 7.39 0.7 76.01 2.8 3.78 20 7.6 78 78 94 587
CRP: C-reactive protein, PCT: procalcitonin, WBC: white blood cell, BUN: blood urea nitrogen, ALT: alanine aminotransferase, AST: aspartate
aminotransferase, LDH: lactate dehydrogenase, IVIG: intravenous immune globulin, and CVVHD: continuous venovenous hemodialysis. Normal values of
laboratory results provided by the examiner institution: lactate: 0,5–2,2mmol/L, CRP: <2,2mg/L, PCT: 0,5𝜇g/L, WBC: 4,5–11,5 G/L, platelets: 150–500G/L,
BUN: 1,8–6,4mmol/L, creatinine: 18–53mmol/L, ALT: <40U/L, AST: <40U/L, and LDH: <340U/L.
CVVHD + CytoSorb
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Figure 2: Course of proinflammatory and immunomodulatory
cytokines before, during, and after combined CVVHD + CytoSorb
treatment.
dramatically 48 hours after CytoSorb therapy and the
diffuse erythroderma, purpura, and petechiae started to fade.
CVVHD was continued for a further 8 days due to pro-
nounced fluid overload, reaching normal rates of diuresis on
day 17, three days after successful extubation and termination
of the initial empiric antibiotic combination therapy. After six
days of total parenteral nutrition the patient was switched to
enteral feeding.
On day 20, her condition deteriorated again with tachyp-
nea and desaturation together with elevated levels of CRP,
PCT. This time, blood cultures revealed a staphylococcal
infection; however, sepsis did not develop during the targeted
antibiotic therapy. After 25 days the patient left the intensive
care unit although her right ankle was still swollen.
The reappearance of fever accompanied by mildly ele-
vated inflammatory laboratory parameters gave rise to the
thought of deep tissue infection. MRI could not rule out
an osteomyelitis of the os naviculare. The patient remained
afebrile while the inflammation of the ankle became smaller
under local conservative therapy. Complex physiotherapy
tried to counteract muscle wasting and decreased tone. The
girl was discharged home after 42 days where she recovered
completely.
3. Discussion
In the present case report, we treated a 5-year-old girl with
Down’s syndrome who developed toxic shock syndrome and
multiple organ failure after an insect bite, using a combination
of CVVHD and hemadsorption. Treatment was associated
with a rapid and significant stabilization of the hemodynamic
situation accompanied by declining catecholamine dosage,
improved respiratory status, and a decrease in inflammatory
mediators within hours after initiation of therapy. Moreover,
the need for platelets decreased dramatically and the diffuse
erythroderma, purpura, and petechiae vanished.
These findings are in line with two published case reports
on the use of CytoSorb in patients with toxic shock syndrome
showing the potential role of this therapy in stabilizing hemo-
dynamics, decreasing vasopressor requirements, improving
lactate clearance, and reducing erythema as short term effects
[2, 3].
The clinical picture in our case was ambiguous. The
cutaneous lesion, as probable origin of the disease, suggested
Streptococcus pyogenes as the causative agent, while the gener-
alized erythroderma was typical for Staphylococcus infection.
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As bacteria fromneither blood cultures nor skin andmucosal
lesions were isolated, the microbiological background of our
case remains unknown. Interestingly, a study that set out to
quantify the ability of theCytoSorb polymer to adsorb a broad
selection of inflammatory pathogen-associated molecular
pattern molecules (PAMPs), damage-associated molecular
pattern molecules (DAMPs), and cytokines from whole
blood in a single compartment in vitro recirculation system
provided that substantial quantities of a broad spectrum of
DAMPS, PAMPS, and cytokines (i.e., S100A8, complement
C5a, procalcitonin, HMGB-1, MIP1-𝛼, IL-6, IFN-𝛾, TNF-𝛼,
Staph enterotoxin TSST-1, and aflatoxin B1) were removed
[4]. Therefore, direct removal of streptococci toxins may
potentially have played a role in the current case.These results
might be of particular interest in a case such as the one
presented herein, where the pathological origin is not clear
but the diagnosis of TSS was established.
One of the striking features of systemic TSS is the speed
of excess cytokine and toxin production. Our patient had
been treated with multiple immune-modulatory therapies
(i.e., hydrocortisone, IVIG, and plasma exchange therapy)
achieving onlymoderate reductions in the laboratory param-
eters that characterize systemic inflammation.However, from
the start of CVVHD/CytoSorb initiation, plasma levels of
inflammatory mediators such as IL-6, IL-10, IFN-𝛾, CRP, and
PCT but also of metabolic parameters (i.e., lactate) started
to decrease rapidly. This attenuation of the inflammatory
response correlated well with the clinical improvement of the
patient.
Previous studies have shown that inflammatory medi-
ators can be removed from the circulation with different
blood purification techniques such as plasma exchange,
high-volume and very high-volume hemofiltration, and a
number of hybrid therapies encompassing high-permeability
hemofiltration, super high-flux hemofiltration, hemadsorp-
tion or coupled filtration, and adsorption [5]. These thera-
peutic modalities have been associated with lower mortality
in patients with sepsis [6, 7]. Whether CytoSorb has the
potential to positively influence mortality in TSS patients
needs to be confirmed in randomized, controlled trials.
However, despite the fact that most experience with
CytoSorb in the clinical setting to date is still limited to
case reports, the first multicenter randomized controlled
study using treatment with CytoSorb hemadsorption in
septic patients with acute lung injury showed that application
of the device over a 7-day treatment period was safe and
effectively decreased the blood concentration levels of several
key cytokines [8–11]. From this perspective, further studies
to elucidate the potential clinical impact of this new therapy
option are urgently warranted.
4. Conclusion
The use of extracorporeal blood purification with a novel
sorbent, CytoSorb, proved potentially beneficial by removing
toxins, cytokines, and other inflammatory mediators in this
case of toxic shock syndrome in a pediatric patient and could
therefore play a future role in the clinicalmanagement of toxic
shock syndrome.Whether CytoSorb has the potential to even
positively influence mortality in patients with toxic shock
syndrome needs to be confirmed in randomized, controlled
trials.
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